Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients

European Journal of Cancer

Volumn 48, Issue 15, 2012, Pages 2442-2450

  Wagner, Ferdinand ^a   Henningsen, Bente ^a   Lederer, Christine ^a   Eichenmüller, Melanie ^a   Gödeke, Jan ^a   Müller Höcker, Josef ^b   Schweinitz, Dietrich Von ^a   Kappler, Roland ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

AKT; Apoptosis; Hepatoblastoma; Rapamycin; Xenograft

Indexed keywords

ALPHA FETOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FEEDBACK SYSTEM; HEPATOBLASTOMA; HIGH RISK PATIENT; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT INDICATION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RISK FACTORS; SIROLIMUS;

EID: 84866735658     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.032     Document Type: Article

References (36)

1. D. von Schweinitz Management of liver tumors in childhood Semin Pediatr Surg 15 1 2006 17 24
2. B. Haberle, U. Bode, and D. von Schweinitz Differentiated treatment protocols for high- and standard-risk hepatoblastoma - an interim report of the German Liver Tumor Study HB99 Klin Padiatr 215 3 2003 159 165
3. G. Perilongo, R. Maibach, and E. Shafford Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma N Engl J Med 361 17 2009 1662 1670
4. J. Zsiros, R. Maibach, and E. Shafford Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study J Clin Oncol 28 15 2010 2584 2590
5. S. Warmann, M. Hunger, and B. Teichmann The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model Cancer 95 8 2002 1795 1801
6. M. Eichenmuller, I. Gruner, and B. Hagl Blocking the hedgehog pathway inhibits hepatoblastoma growth Hepatology 49 2 2009 482 490
7. Y. Wei, M. Fabre, and S. Branchereau Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas Oncogene 19 4 2000 498 504
8. S.G. Gray, T. Eriksson, and C. Ekstrom Altered expression of members of the IGF-axis in hepatoblastomas Br J Cancer 82 9 2000 1561 1567
9. W. Hartmann, J. Kuchler, and A. Koch Activation of phosphatidylinositol- 3′-kinase/AKT signaling is essential in hepatoblastoma survival Clin Cancer Res 15 14 2009 4538 4545
10. H. Seeliger, M. Guba, A. Kleespies, K.W. Jauch, and C.J. Bruns Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis Cancer Metastasis Rev 26 3-4 2007 611 621
11. X. Wan, N. Shen, A. Mendoza, C. Khanna, and L.J. Helman CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling Neoplasia 8 5 2006 394 401
12. A. Misawa, H. Hosoi, K. Tsuchiya, and T. Sugimoto Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN Int J Cancer 104 2 2003 233 237
13. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2 2002 128 135
14. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 3 2006 471 484
15. A.A. Schnitzbauer, C. Zuelke, and C. Graeb A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 10 2010 190
16. M. Rizell, M. Andersson, and C. Cahlin Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer Int J Clin Oncol 13 1 2008 66 70
17. I. Doi Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma Gann 67 1 1976 1 10
18. T. Pietsch, C. Fonatsch, and S. Albrecht Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma Lab Invest 74 4 1996 809 818
19. D. Lopez-Terrada, S.W. Cheung, M.J. Finegold, and B.B. Knowles Hep G2 is a hepatoblastoma-derived cell line Hum Pathol 40 10 2009 1512 1515
20. M. Eichenmuller, B. Hemmerlein, D. von Schweinitz, and R. Kappler Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma Br J Cancer 103 1 2010 43 51
21. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
22. E. Galanis, J.C. Buckner, and M.J. Maurer Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 23 2005 5294 5304
23. S. Chan, M.E. Scheulen, and S. Johnston Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 23 2005 5314 5322
24. D.A. Krueger, M.M. Care, and K. Holland Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 19 2010 1801 1811
25. A.M. Hammill, M. Wentzel, and A. Gupta Sirolimus for the treatment of complicated vascular anomalies in children Pediatr Blood Cancer 57 6 2011 1018 1024
26. A. Tejani, S. Alexander, and R. Ettenger Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis Pediatr Transplant 8 2 2004 151 160
27. A.C. Piguet, D. Semela, and A. Keogh Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma J Hepatol 49 1 2008 78 87
28. D. Nielsen, A. Briem-Richter, and M. Sornsakrin The use of everolimus in pediatric liver transplant recipients: first experience in a single center Pediatr Transplant 15 5 2011 510 514
29. X. Zhou, M. Tan, and V. Stone Hawthorne Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 10 20 2004 6779 6788
30. V.J. Jasinghe, Z. Xie, and J. Zhou ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft J Hepatol 49 6 2008 985 997
31. A. Boulay, S. Zumstein-Mecker, and C. Stephan Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res 64 1 2004 252 261
32. S.A. Lang, A. Gaumann, and G.E. Koehl Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model Int J Cancer 120 8 2007 1803 1810
33. B. Hartmann, G. Schmid, and C. Graeb Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy Kidney Int 68 6 2005 2593 2598
34. J. Lieber, B. Kirchner, and C. Eicher Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells Pediatr Blood Cancer 55 6 2010 1089 1095
35. K.N. Koh, M. Park, and B.E. Kim Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma Pediatr Blood Cancer 57 4 2011 554 560
36. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 13 2007 1932 1940